Media Statement:

CYTOCHROMA AND GENZYME SETTLE LAWSUIT

Markham, Ontario, Canada — April 16, 2007 — Cytochroma Inc. announced that the lawsuit filed in August 2006 by Genzyme Corporation in the United States District Court, Western District of Wisconsin has been settled by the parties.

On August 8, 2006, Genzyme filed a complaint in the United States District Court, Western District of Wisconsin against Cytochroma Inc., Proventiv Therapeutics LLC and three former Bone Care International employees.  The complaint, alleging misappropriation of Vitamin D-related trade secrets, was amicably resolved and the case has been formally dismissed.  The terms of the settlement were not disclosed.

“Cytochroma has remained on track for meeting its financing and clinical development milestones despite the intercurrent lawsuit,” commented Dr. Alan Lewis, Chairman of the Board. “The recent settlement with Genzyme adds further momentum to Cytochroma for achieving its corporate objectives.”

About Cytochroma Inc.

Cytochroma is an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of diseases and disorders related to vitamin D hormone deficiency. The Company has an advanced portfolio of new products targeting vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition, the Company is developing novel vitamin D therapies to treat hyperproliferative disorders such as cancer and psoriasis.

For information contact:

Eric J. Messner
Vice President
Commercial Operations
905-479-5306 ext. 338
eric.messner@cytochroma.com

< go back >